Curebase plans to use the funds to move further into the pharma and biotech spaces. Here are the top-line bullets you need to know.
Curebase, a clinical trial services provider, has raised $40M in a Series B. The round drew participation from BOLD Capital Partners, GGV Capital, Gilead Sciences, and Xfund, among others.
HOW’S THE COMPANY PERFORMING?
- California-based Curebase offers software to support decentralized clinical trial operations.
- The company has helped run 50+ studies to date and witnessed 300% to 400% growth year-over-year.
- Curebase has over 45 customers using its platform.
- It supports clinical trials across the US, Canada, the UK, and France.
- Curebase is currently available in 3 languages across 4 countries.
Source: Curebase
WHY DOES THE MARKET MATTER?
- The global clinical trials market is expected to reach a value of $69.3B by 2028, growing at a CAGR of 5.7%, according to Grand View Research.
- The rising prevalence of chronic diseases, the growing demand for personalized medication, and the globalization of clinical trials are some of the key factors contributing to market growth.
- The increasing application of AI to clinical trial solutions is also driving market growth. This tech has proven to help better identify patients for clinical trials, speed up clinical trials, and bring drugs to market faster.
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
